Tassi P, Ormas P, Madonna M, Carli S, Belloli C, De Natale G, Ceci L, Marcotrigiano G O
Department of Veterinary Parasitology, Faculty of Veterinary Medicine, University of Bari, Italy.
Res Vet Sci. 1994 Mar;56(2):144-50. doi: 10.1016/0034-5288(94)90096-5.
The pharmacokinetic profile of antimony in dogs was defined by administering it intravenously, intramuscularly and subcutaneously as N-methylglucamine antimoniate at a dose of about 25.65 mg of antimony kg-1 bodyweight. The results showed a different half-life for the three routes of administration: 20.5, 42.1 and 121.6 minutes for the intravenous, intramuscular and subcutaneous routes, respectively; peak time values (Tmax) were also different for the intramuscular (90 to 120 minutes) and subcutaneous (210 to 240 minutes) injection. The apparent bioavailability of antimony was > 100 per cent for the intramuscular and 100 per cent for the subcutaneous routes. The data obtained showed a relevant difference in the behaviour of the drug in the dog in comparison to that in humans.
通过以约25.65毫克锑/千克体重的剂量静脉内、肌肉内和皮下注射N - 甲基葡糖胺锑酸盐来确定锑在犬体内的药代动力学特征。结果显示三种给药途径的半衰期不同：静脉内、肌肉内和皮下途径分别为20.5、42.1和121.6分钟；肌肉注射（90至120分钟）和皮下注射（210至240分钟）的达峰时间值（Tmax）也不同。锑的表观生物利用度肌肉内途径大于100%，皮下途径为100%。所获得的数据表明，该药物在犬体内的行为与在人体内的行为存在显著差异。
